Armando Armas M.D. Email & Phone Number

Thousand Oaks, Ca, Us

Foster City, Ca, Us

A Phase II, Open-Label Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic MalignanciesA Phase II, Open-Label Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies

Foster City, Ca, Us

Associated with Palm Beach Institute of Hematology and Oncologyo A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic LeukemiaA Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Direct operations of Medical Oncology clinics & infusion therapy unit, coordination of care between various specialists including 2 Radiation Oncologists, running tumor boards, chairman of Cancer Care committee, developing clinical trial programs, serving as Principal Investigator on new studies, developing relationships with CRO’s, medical science Liaison of major pharmaceutical companies, performing outreach to rural communities, & established oversight & implementation of Commission on Cancer (CoC) “Cancer Program Standards”. CoC Cancer Program Standards are a set of guidelines put out by the American College of Surgeons. ● Achieved Certification by CoC as community cancer center, hired new radiation oncologist to meet demands of rapidly growing patient referral base, expanded existing clinical trial program to include industry-sponsored innovative Phase I-III clinical trials & added high priority clinical trials through SWOG. o Directed team responsible for achievement of initial CoC certification with 3 commendations; exceptional for a new cancer center. o Established community outreach program providing access to rural communities on Western Slope as integral standard of the CoC.● Focus on research has been to provide patients with access to innovative translational therapies & immunotherapies. Enrolled patients on novel clinical trials with combined checkpoint inhibitors, immune modulating therapies, cell signaling therapies & many other translational drugs. o Perfect compliance record with clinical monitors, regulatory agencies, IRB’s, & FDA.● Continue to serve on medical advisory boards of both large & newly emerging pharmaceutical companies in areas of drug development, clinical trial design, regulatory compliance, marketing, & support.• Clinical Development with cancer Phase I Studies • Biotechnology • Partnered with Pharmaceutical Industry for Regulatory Affairs • Medical Affairs – Conducted post-marketing of clinical trials

A Randomized, Open-Label Phase III Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who have Failed Prior Gemcitabine-based Therapy

Sunnyvale, California, Us

Private practice-based consortium in Palm Beach County, Florida with participation of five local Oncology clinics accruing patients to 25 active clinical trials ranging from early Phase I studies to Phase III studies.● Principal Investigator to conduct 25 active clinical trials, accrued over 50 patients per year. Included translational therapies such as TDM, Abraxane, Cetuximab, Nplate, and many other drugs as well as T-cell and vaccine directed therapies. Sub-investigator in early trials with Ipilimumab.

Us

Oncologist and Clinical Trialist

Fellowship, Medical Oncology

Medical Oncology

Internal Medicine

Doctor Of Medicine - Md, Oncology And Cancer Biology

Doctor Of Medicine (M.D.)

Bachelor Of Arts - Ba, Chemistry

Bachelor Of Arts (B.A.), Chemistry